Clinical Trial Search

Primary: Change From Baseline in Fasting Plasma Glucose (FPG) at Day 15 — 32.8; 37.9; 56.0; 2.0 mg/dL

Primary: AALL08P1 Safety Outcome — 50.0 percentage of participants

Primary: Number of Subjects Experiencing Dose Limiting Toxicity (DLT) — 0; 0; 0 subjects

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Standard Hematology — 0; 0; 0; 0 participants

Primary: Number of Participants With Adverse Events During NKAE Treatment — 2 participants

Primary: Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Strongly PD-L1 Positive Participants — 27.3 Percentage of…

Primary: Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 6147; 6141 nanomol…

Primary: Maximum Measured Concentration (Cmax) at Steady State for Telmisartan — 970; 857; 895 ng/mL

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 21; 3; 3; 5 participants

Primary: Nightly CPAP Use — 6.4; 5.8 hours/night — p=0.20

Primary: Mean Reduction From Baseline in Log10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 5 - HCV GT1 — 4.25; 4.40; 3.56; 0.00 IU/mL

Primary: Number of Subjects With Dose-limiting Adverse Events — 0; 2; 3; 0 participants

Primary: Effect of HSV-2 Suppression on HCV Viral Load. — .18; .03 log(IU/mL)

Primary: Number of Vaccinated Participants Who Experienced Adverse Events by Nature and Severity. — 0; 3; 3; 2 participants

Primary: Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin — 24.8; 48.4; 118 ng/mL